Barrington raised the firm’s price target on Haemonetics (HAE) to $94 from $93 and keeps an Outperform rating on the shares following what the firm calls a “mixed bag quarter.” Still, Haemonetics updated its FY26 outlook with what the firm calls “solid guidance.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics price target lowered to $75 from $88 at Citi
- Haemonetics reports Q3 adjusted EPS $1.31, consensus $1.25
- Haemonetics narrows FY26 adjusted EPS view to $4.90-$5.00 from $4.80-$5.00
- HAE Upcoming Earnings Report: What to Expect?
- Balancing Plasma Strength Against Vascular Closure Uncertainty: Maintaining a Neutral (Hold) View on Haemonetics